← 返回

揭示 CD40 激动作用增强免疫检查点阻断的潜力

英文原题:Uncovering the Potential of CD40 Agonism to Enhance Immune Checkpoint Blockade.

查看英文原题

Uncovering the Potential of CD40 Agonism to Enhance Immune Checkpoint Blockade.

PubMed 2024/01/05(内容时间) Clin Cancer Res Q1 · IF 10.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

在这篇CCR Translations中,我们讨论了CD40激动作用的治疗潜力,它能刺激抗原呈递细胞(APC)激活效应T细胞和NK细胞。CD40激动作用可能导致干扰素激活的、T细胞炎症的肿瘤微环境的形成,并有可能促进免疫检查点阻断的长期应答。参见Weiss等人的相关文章,第74页。

展开英文摘要原文

In this CCR Translations, we discuss the therapeutic potential of CD40 agonism, which stimulates antigen-presenting cells (APC) to activate effector T and NK cells. CD40 agonism may lead to development of an interferon-activated, T cell-inflamed tumor microenvironment and has the potential to facilitate long-term response with immune checkpoint blockade. See related article by Weiss et al., p. 74.

论文信息

作者
Wu RC、Luke JJ
第一作者单位
The Ohio State University James Comprehensive Cancer Center and Division of Medical Oncology, Columbus, Ohio.United States
通讯作者单位
UPMC Hillman Cancer Center and the University of Pittsburgh Department of Medicine, Pittsburgh, Pennsylvania.United States
文献类型
美国 NIH 资助研究 · 评论
期刊
Clinical cancer research : an official journal of the American Association for Cancer Research2024 Jan 5
原文标识
PubMed 37870487 · DOI 10.1158/1078-0432.CCR-23-2437